logo
Plus   Neg
Share
Email

Rigel Pharma Says Phase 2 Trial Of Fostamatinib For COVID-19 Met Primary Endpoint Of Safety

Biotechnology company Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19.

The trial, being conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), and Inova Health System, met its primary endpoint of safety. Fostamatinib reduced the incidence of Serious Adverse Events (SAEs) by half.

Based on these data, Rigel plans to discuss the potential for emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) of fostamatinib as a treatment for hospitalized patients with COVID-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Centers for Disease Control and Prevention has endorsed the safety and effectiveness of the Pfizer-BioNTech COVID-19 vaccine and its use in 12- through 15-year-old adolescents following the recommendation of its independent advisory committee. Dash Xclusive recalled all lots of weight loss and anxiety dietary supplement Imperia Elita Vitaccino Coffee for containing undeclared sibutramine and fluoxetine, the U.S. Food and Drug Administration or FDA said in a statement. The company said the presence of sibutramine and fluoxetine in product renders it an unapproved drug or supplement for which safety and efficacy has not been established. MGM Resorts International (MGM) announced Wednesday that the Nevada Gaming Control Board has approved a return to 100 percent occupancy and no social distancing on the gaming floors located inside the company's nine Las Vegas Strip properties. The properties are - Bellagio Resort & Casino,ARIA Resort...
Follow RTT